The following will discuss the mechanism and characteristics of mAb pharmacokinetics in terms of absorption, distribution, and elimination. The bioavailability of protein drugs such as antibodies is ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

Shanghai Ark Biopharmaceutical (ArkBio) has concluded enrolment and dosing for a Phase I trial of fully human monoclonal ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients ...

Assessing the pharmacokinetics (PK) of antibody-drug conjugates (ADCs) in both preclinical and clinical settings is crucial for their development. Biotransformation processes can lead to the ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs ... human immunoglobulin gamma monoclonal antibodies (hIgG mAbs) are a most promising ...

The data and evaluations of pharmacodynamics, pharmacokinetics ... AU-007 is the first human IgG1 monoclonal antibody designed by leveraging artificial intelligence to enter a human clinical ...

Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK ...